Eli Lilly Terminates Study Of Bimagrumab In Obesity
Synopsis
A U.S. registry of clinical trials shows that the study has been terminated for strategic business reasons.
Eli Lilly & Co. (LLY) has halted the study of its drug Bimagrumab, alone or in combination with its approved weight-loss drug Tirzepatide, in patients with obesity.
A U.S. registry of clinical trials indicates that the study has been terminated due to strategic business reasons. The purpose of the study was to see how well and how safely Bimagrumab, Tirzepatide, and the combination worked in lowering body weight in participants with obesity or overweight and type 2 diabetes.
Bloomberg first reported the termination of the trial. Following the development, the stock traded 0.59% lower in Thursday’s pre-market session.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.